Can resveratrol-copper be used to prevent metastasis without trials? | Top Vip News

Great work by researchers at Tata Memorial Center (TMC), Mumbai, has found conclusive evidence in cell lines, animal studies and two phase 2 clinical trials that cell-free chromatin fragments that are released from dying cells They have the ability to easily enter healthy cells in the body and integrate into their genomes and trigger DNA damage by breaking the double strand of DNA, causing apoptosis (programmed cell death) and inflammation. Based on these studies, a team led by Dr. Indraneel Mittra, professor emeritus of the Department of Surgical Oncology at TMC, had proposed that “the repeated and permanent attack on healthy cells by cell-free chromatin fragments may be the underlying cause of aging and multiple ages.” -Related disorders, including cancer.” They also found that using a combination of two nutraceuticals (resveratrol and copper) minimizes the damaging effects of cell-free chromatin fragments.

Researchers have gathered enough evidence to show that the toxic effects of chemotherapy are primarily caused by fragments of free chromatin that emerge from dying cells and continue the vicious cycle of killing healthy cells and causing inflammation. This finding challenges the dogma that toxicity caused by chemotherapy is due to the drugs’ direct damaging effect on healthy cells.

Based on preclinical studies that showed promising results when using the resveratrol-copper combination, Dr. Mittra and other TMC researchers tested it in 25 patients undergoing autologous bone marrow transplantation for multiple myeloma and 30 patients with advanced gastric cancer. In both studies, chemotherapy toxicity was much lower among patients who received the resveratrol-copper combination.

Evidence from preclinical studies also suggests that resveratrol and copper nutraceuticals may prevent the metastatic spread of cancer. Researchers had previously reported that free chromatin particles released by dying cancer cells are potentially oncogenic. Studies in mice by the team showed that oncogenes contained in cell-free chromatin fragments were transported by the blood and accumulated in the brain cells of the mice. Although oncogenes in the brain can potentially lead to metastasis, the study did not investigate whether the spread of oncogenes to brain cells actually led to the development of metastasis.

TMC statement

A statement issued on March 1 by TMC categorically stated that the effectiveness of resveratrol-copper in reducing the toxicity of chemotherapy or increasing cures in cancer patients “has not yet been established and is currently under investigation.” The statement was released after Dr Rajendra Badwe, senior researcher at TMC, told NDTV that the nutraceutical to reduce the toxicity of chemotherapy will be available in June this year after FSSAI approval. Several media outlets wrongly reported that the nutraceutical to be approved by FSSAI is for preventing cancer metastasis.

Based on extensive preclinical studies and two phase 2 clinical trials, there is sufficient evidence to believe that resveratrol-copper would reduce chemotoxicity in cancer patients, says Dr. Mittra. The Hindu in an email. “Evidence from preclinical studies suggests that the combination of resveratrol and copper may prevent metastatic spread. Randomized trials now needed to establish amount of benefit [in reducing chemotoxicity]. Results from at least one randomized trial will hopefully be available within about a year. In the meantime, and once resveratrol-copper is certified as a nutraceutical, it will be up to each individual to take it for themselves. [any of] instructions above if you wish,” says Dr. Mittra.

Despite the absence of clinical trials supporting the use of a combination of resveratrol and copper to prevent metastasis, Dr. Mittra sees no problem with patients using the nutraceutical to prevent cancer metastasis as soon as it is available. . “Once resveratrol-copper is approved as a nutraceutical, anyone should be free to take it. Although at this point we only have preclinical evidence that it prevents metastasis if someone decides to take resveratrol-copper for this indication, being a non-toxic combination, it is unlikely to cause any harm,” he says.

“Resveratrol-copper is probably the nutraceutical product that has the most scientific evidence supporting it for various conditions. For example, our preclinical studies have shown that it slows aging parameters, such as the removal of amyloid plaques responsible for Alzheimer’s disease. Resveratrol-copper also prevents telomere shortening, inflammation, DNA damage and chromosomal abnormalities and reduces blood cholesterol and glucose levels. Therefore, resveratrol-copper can have many other health benefits for the person who decides to take it,” adds Dr. Mittra. “I have personally been taking resveratrol and copper tablets for the last three years without any side effects. The mother of a TMC oncologist who suffers from Alzheimer’s disease has been taking resveratrol-copper tablets for several months and has noticeably improved her cognitive score and overall mental state.”

On why researchers are trying to get the combination approved by the FSSAI as a nutraceutical and not as a drug by drug regulator CDSCO, Dr Mittra says TMC did not take the nutraceutical route willingly. “We had tied up with an industry partner who was sourcing resveratrol and copper from two different suppliers to manufacture resveratrol and copper tablets in a specific formulation. The industry partner was unable to get its resveratrol-copper formulation approved by DCGI as the latter insisted that the respective suppliers from which the resveratrol and copper were sourced register their products with DCGI from their own GMP facilities. The sellers were not willing to do it. As a result, the industrial partner handed over the project to its subsidiary that is dedicated to the nutraceutical industry.”